Study endpoints
Fatigue, pustulation, Psoriasis, pain
SECONDARY, CHRONIC ILLNESS, PSORIASIS
The primary endpoint was a GPPGA pustulation subscore of 0 (no visible pustules) at the end of Week 1. The key secondary endpoint was a GPPGA total score of 0 or 1 (clear or almost clear skin) at the end of Week 1. Patient‐reported outcomes (PROs) were pain visual analog scale (pain VAS), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐Fatigue), Dermatology Quality of Life Index (DLQI), and Psoriasis Symptom Scale (PSS). For these scales, minimal clinically important differences (MCIDs) were defined as a 30‐point decrease, a 4‐point increase, a 4‐point decrease, and a 2‐point decrease, respectively, from baseline.